Predictors of cardiovascular death in NAVIGATOR participants as identified in a multivariable Cox proportional hazard stepwise selection model
| Variable | HR (95% CI) | Wald χ² | p Value |
|---|---|---|---|
| Age (per 10 years) | 1.77 (1.47 to 2.12) | 37.6 | <0.0001 |
| Latin America vs North America | 2.68 (1.82 to 3.96) | 24.6 | <0.0001 |
| Coronary heart disease* | 2.04 (1.53 to 2.72) | 23.9 | <0.0001 |
| Heart failure | 2.27 (1.56 to 3.30) | 18.3 | <0.0001 |
| Gender (male vs female) | 1.90 (1.41 to 2.57) | 17.5 | <0.0001 |
| Current smoker | 2.00 (1.41 to 2.83) | 15.1 | 0.0001 |
| Significantly abnormal vs normal ECG | 2.01 (1.38 to 2.92) | 13.3 | 0.0003 |
| eGFR (per 10 ml/min/1.73 m2 decrease below 60 ml/min/1.73 m2) | 1.42 (1.16 to 1.75) | 11.1 | 0.0009 |
| Urine albumin/creatine ratio (log units) | 1.16 (1.06 to 1.27) | 10.1 | 0.0015 |
| Cerebrovascular disease* | 1.72 (1.23 to 2.40) | 10.0 | 0.0016 |
| Atrial fibrillation or flutter | 1.81 (1.24 to 2.65) | 9.4 | 0.0021 |
| Haemoglobin (per 10 g/l decrease) | 1.15 (1.04 to 1.27) | 7.4 | 0.0066 |
| Chronic obstructive pulmonary disease | 1.70 (1.16 to 2.49) | 7.4 | 0.0066 |
| Insignificantly abnormal vs normal ECG | 1.60 (1.13 to 2.26) | 7.1 | 0.0076 |
| Other vs North America | 2.32 (1.23 to 4.40) | 6.7 | 0.0098 |
| Peripheral artery disease* | 1.66 (1.08 to 2.55) | 5.4 | 0.0203 |
| Renal dysfunction | 1.97 (1.09 to 3.56) | 5.0 | 0.0250 |
| Asia vs North America | 0.66 (0.30 to 1.47) | 1.0 | 0.3090 |
| Europe vs North America | 1.05 (0.74 to 1.48) | 0.1 | 0.7993 |
*For definitions see table 1 footnote.
eGFR, estimated glomerular filtration rate; NAVIGATOR, Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research.